Free tool
FAERS Monitor: Kinevac
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017697 or its brand name (Kinevac, Sincalide). Reports on generic versions are filed under their own applications.
Reports
153
Serious
38
25% of reports
Hospitalization
17
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective38
- drug effect decreased35
- multiple use of single-use product29
- no adverse event24
- nausea13
- product quality issue11
- therapeutic product effect decreased11
- diarrhoea8
- gallbladder disorder8
- pain8
- abdominal pain7
- chills7
- dizziness7
- hepatobiliary scan abnormal7
- product physical consistency issue7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 12 |
| 2014 | 37 |
| 2015 | 14 |
| 2016 | 20 |
| 2017 | 7 |
| 2018 | 10 |
| 2019 | 20 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 6 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,006 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatobiliary scan abnormalSignal | 7 | 8027.1 | 3809.0 | 45,767 |
| multiple use of single-use productSignal | 29 | 713.8 | 513.8 | 19,837 |
| product physical consistency issueSignal | 7 | 174.1 | 84.4 | 1,037 |
| drug effect decreasedSignal | 35 | 89.4 | 66.8 | 2,977 |
| gallbladder disorderSignal | 8 | 61.6 | 31.4 | 419 |
| therapeutic product effect decreasedSignal | 11 | 33.8 | 19.1 | 318 |
| no adverse eventSignal | 24 | 18.2 | 12.6 | 377 |
| product quality issueSignal | 11 | 11.1 | 6.3 | 92 |
| chillsSignal | 7 | 8.2 | 4.0 | 38 |
| abdominal painSignal | 7 | 4.1 | 2.0 | 14 |
| drug ineffectiveSignal | 38 | 4.0 | 3.0 | 87 |
| nauseaSignal | 13 | 2.3 | 1.3 | 8 |
| dizziness | 7 | 1.9 | 0.9 | 2 |
| pain | 8 | 1.8 | 0.9 | 2 |
| diarrhoea | 8 | 1.7 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.